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ABSTRACT Recent studies have shown that confluent
cultured fibroblasts must be rendered competent by a factor
contained in platelets before they can respond to plasma com-
ponents and progress from Go to S phase of the cell cycle. So-
matomedin-C is one of the components of platelet-poor plasma
necessary for cell cycle progression, but other factors present
in somatomedin-C-deficient plasma are also required. Because
both competence and progression factors contained in soma-
tomedin-C-deficient serum modulate somatomedin-C action
in fibroblasts, this study was undertaken to examine their pos-
sible influence on the binding of '25I-labeled somatomedin-C.
Exposure of BALB/c 3T3 fibroblasts to high concentrations of
platelet-derived growth factor alone prevented the time-de-
pendent decrease in somatomedin-C binding which occurs in
serum-free medium. Lower concentrations of the growth factor
or 5% (vol/vol) platelet-poor plasma reduced but did not abolish
this decrease. In contrast, sequential addition of platelet-derived
growth factor followed by platelet-poor plasma resulted in a
75% increase in 125I-labeled somatomedin-C binding over basal
levels during the first 2 hr. Binding increased by 125% when
somatomedin-C-deficient platelet-poor plasma was substituted
for normal platelet-poor plasma. The hormonal induction of
somatomedin-C receptors appears to be a mechanism whereby
peptide growth factors such as platelet-derived growth factor
may condition the cell to respond optimally to somato-
medin-C.
BALB/c 3T3 fibroblasts rendered quiescent by density-de-
pendent growth inhibition can be stimulated to initiate DNA
synthesis by the sequential action of at least three serum com-
ponents. Transient exposure to platelet-derived growth factor
(PDGF) initiates cell cycle traverse by rendering quiescent cells
competent to respond to factors contained in platelet-poor
plasma (PPP) (1, 2). After exposure to normal PPP, competent
cells progress through S phase after a lag of 12 hr (3). The active
components of PPP, termed progression factors, include so-
matomedin-C (SM-C) and unknown factor(s) contained in
SM-C-deficient PPP. Exposure to SM-C-deficient plasma allows
progression to a growth arrest point 6 hr before DNA synthesis.
Addition of exogenous SM-C causes the resumption of pro-
gression through G1, resulting in DNA synthesis after a lag of
an additional 6 hr (4). The mechanism by which PDGF and
SM-C-deficient PPP act to permit limited progression is un-
known.
Polypeptide growth factors such as insulin (5, 6), SM-C (7),
somatomedin-A (8), insulin-like growth factor I (9), multipli-
cation-stimulating activity (10), and epidermal growth factor
(EGF) (11) have specific receptors on cultured cells types such
as rat hepatocytes and chicken embryo, mouse, and human
fibroblasts. These studies have made quantitative comparisons
between the capacity of a peptide growth factor to bind its
specific cellular receptor and its ability to stimulate DNA
synthesis (12). Studies to determine the effect of one mitogen
on the binding of another labeled mitogen usually have been
limited to experiments that quantitate direct competition for
specific receptors (13-15). In general, these studies have
characterized this competitive peptide interaction by using
asynchronous or noncycling cell populations (16, 17). Recently
it has been demonstrated that PDGF can modulate EGF
binding in Swiss 3T3 cells by a process other than competitive
displacement (18). Because PDGF plus other factors in SM-
C-deficient PPP allow cells to respond to SM-C, we have ex-
amined the possible influence of these two serum components
on the binding of SM-C to BALB/c 3T3 cells. Our data suggest
that PDGF and the unknown factor(s) in SM-C-deficient
plasma act synergistically to bring about a significant increase
in SM-C binding to BALB/c 3T3 cells.
MATERIALS AND METHODS
Cell Culture. BALB/c 3T3 cells (clone AS1) were plated at
a density of 20,000 cells on 35-mm culture dishes (Falcon) in
Dulbecco's modified Eagle's medium (Flow Laboratories,
Rockville, MD) supplemented with 10% (vol/vol) calf serum
(Colorado Serum, Denver, CO). Medium was changed on the
third day after plating and the cell cultures were used 3-4 days
after reaching confluency. Cells grown in this manner were
shown to be quiescent (i.e., 2% of cells incorporate [3H]thymi-
dine into DNA in 36 hr).
Mitogens and Serum Components. Material was extracted
from outdated human platelets by described methods (19).
These extracts were applied to a CM 50 Sephadex column and
eluted with a 0.1-1.0 M NaCl gradient (20). Each fraction was
tested for mitogenic activity by quantitating the percentage
of BALB/c 3T3 cells that synthesized new DNA. Specifically,
quiescent monolayers were simultaneously exposed to in-
creasing concentrations of partially purified PDGF added to
modified Eagle's medium containing 5% (vol/vol) PPP and
[3H]thymidine (1.0 ,uCi/well; 1 Ci = 3.7 X 1010 becquerels).
After 36 hr, the plates were processed by an autoradiographic
method (19). The active fractions were pooled and stored at
-20°C. This material was determined to be free of SM-C by
radioimmunoassay. Fibroblast growth factor (FGF), purified
from bovine brain tissue, was purchased from Collaborative
Research (Waltham, MA). This material was described by the
manufacturer to have a single component as determined by
electrophoresis and to be greater than 99% pure. PPP was
prepared by described methods (1). SM-C-deficient PPP (hy-
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popituitary PPP) was obtained from patient. with documented
growth hormone deficiency who had not received growth
hormone treatment for several months. The preparations of
hypopituitary PPP used in this study contained SM-C levels
below the radioimmunoassay detection limits (less than 2.4
ng/ml).
SM-C was purified as described by Svoboda et al. (21), and
by multiple criteria it was judged to be no less than 90% ho-
mogeneous. 125I-Labeled SM-C (125I-SM-C) was prepared as
described (22). When compared to native, noniodinated SM-C,
this material had a similar threshold for binding, binding
dose-response curve, and saturation concentration.
Experimental Incubation Procedures. Spent medium was
removed from quiescent cell cultures and replaced by fresh
media containing partially purified PDGF (0.75-5.0 Ag/ml)
or FGF (50 ng/ml). (In the experiment described in Fig. 2, one
group of monolayers was exposed to PPP alone without prior
exposure to PDGF.) The cells then were incubated at 370C for
5 hr, except as noted. The medium containing PDGF or FGF
was removed and the cells were washed extensively (modified
Eagle's medium alone) and incubated at 370C for various times
in the presence of fresh medium containing either 5% PPP or
5% hypopituitary PPP. At hourly intervals, duplicate mono-
layers were washed three times with modified Eagle's medium
and the binding of 125I-SM-C was determined.
Procedure for 125I-SM-C Binding. After the extensive
washing, the cells were exposed to binding medium, which
contained 20mM Hepes/0.1% bovine serum albumin, pH 7.4,
and 0.5-1.5 ng of 125I-SM-C per ml (125 1Ci/,g) (final incu-
bation volume was 0.5 ml). Cells were incubated at 40C for 2
hr in the medium, after which the medium was aspirated and
the cells were washed three times with phosphate-buffered
saline. Cell-associated radioactivity was determined in a
Beckman gamma spectrometer (efficiency = 65%) after the
cells were solubilized in 1.0 ml of 0.2 M NaOH.* The cell
number was determined at the initiation of each experiment
by a particle counter on duplicate cell samples. Results are ex-
pressed as cpm of 125I bound per 5 X 105 cells. Correction for
nonspecific binding was made by subtracting the radioactivity
bound in the presence of an excess of unlabeled SM-C (400
ng/ml) from the total radioactivity bound. The amount of
nonspecifically bound '25I-SM-C was consistently less than 15%
of the total. Total radioactivity bound was in the range of 3-5%
of the total radioactivity added.
RESULTS
Binding of 125I-SM-C to Quiescent BALB/c 3T3 Cells. The
effects of time and temperature on binding were analyzed by
using a subsaturating concentration of 125I-SM-C (1.4 ng/ml).
When cells were incubated at 370C in modified Eagle's me-
dium, a progressive increase in binding was observed during
the first 90 min of incubation. This was followed by a decline
in binding over the next 2 hr (Fig. 1A). To determine whether
degradation of 125I-SM-C was the cause of this decrease, we
removed the media containing 125I-SM-C that had been used
for previous incubation and incubated them with a preparation
of human placental membranes (200,g of protein per tube)
for 18 hr (4°C; 50 mM Tris-HCl, pH 7.4). The percent of spe-
cific binding was then determined. A comparison between the
radioactivity bound in the presence of 125I-SM-C that had been
incubated for 3 hr with cells and the radioactivity bound using
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FIG. 1. Time course of SM-C binding to BALB/c 3T3 fibroblasts
at 370C (A) and 40C (B). 125I-SM-C (1.4 ng/ml) was added to cells in
modified Eagle's medium containing 20 mM Hepes and 0.1% albumin.
After the times indicated, cells (281,000 cells per dish) were washed
three times in phosphate-buffered saline and dissolved in 0.2 M
NaOH. The bound radioactivity was then determined. Specific
binding was determined by subtracting the radioactivity bound in an
excess of native SM-C.
after the 3-hr incubation, but this difference was not signifi-
cant.t
The time course for binding of 125I-SM-C to BALB/c 3T3
cells at 40C differed from that observed at 370C (Fig. 1B). At
4°C, binding increased rapidly to approximately 90% of its
maximum by 2 hr and show no decline during 12 hr of incu-
bation. In additional experiments we observed that 125I-SM-C
that bound at 40C could be dissociated intact at 4°C. Disso-
ciation was accelerated at 370C, but time-dependent degra-
dation of the hormone occurred (approximately 50% loss of
specific binding after 13 hr of incubation). The SM-C receptor
in BALB/c 3T3 fibroblasts has a spectrum of specificity similar
to SM-C receptors in other tissues (i.e., liver or placental
membranes). PDGF (0.5-20 ,ug/ml), FGF (10-400 ng/ml), or
EGF (0.02-1.0 ug/ml) did not show any significant displace-
ment at concentrations tested. Insulin was competitive at con-
centrations between 200 ng and 10 ,ug per ml.
SM-C Binding Decreases in Quiescent BALB/c 3T3 Cells
After Incubation in Medium Deficient in PDGF. To deter-
mine if PDGF or factors in PPP could enhance binding of
SM-C, we incubated quiescent cells in fresh medium that had
been supplemented with either PPP or PDGF. After various
times of incubation, 125I-SM-C binding was measured. There
was a time-dependent decrease in the amount of 125I-SM-C
bound to the cells incubated in medium supplemented with 5%
PPP (Fig. 2). When quiescent cells were incubated in medium
supplemented with 4.8 Ag of partially purified PDGF per ml,
there was no decline in binding. In contrast, a decrease in the
concentration of PDGF from 4.8 to 0.76 ,g/ml resulted in a
dose-dependent decrease in binding. Likewise, when the con-
centration of PPP was lowered to 1%, a greater loss of SM-C
binding occurred (4 at 6 hr). Increasing the PPP concentration
to 10%, however, was not accompanied by a further increase
in SM-C binding. The loss of SM-C binding that occurred in the
presence of low PPP or PDGF concentrations was consistently
present during incubation at 37°C but could be minimized
t In another set of experiments, 3T3 cells that had been incubated with
125I-SM-C for the times indicated in Fig. 1A were removed, washed,
and exposed to fresh 125I-SM-C (2 ng/ml) for 4 hr at 40C. Under these
conditions, no increase of 125I-SM-C binding was detectable and the
time-dependent loss of receptor number remained apparent. Addi-
tional studies showed that this loss of receptor binding was dependent
upon the contribution of SM-C to which the cells were initially ex-
posed.
* At least 95% of the NaOH-solubilized 125I-containing material could
be consistently recovered by scraping plates with a rubber po-
liceman.
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FIG. 2. Effect of exposure to PDGF or to plasma on 125I-SM-C
binding. Quiescent cells (322,000 cells per dish) were exposed to me-
dium containing PDGF or PPP for various times at 371C. This me-
dium was removed, cells were washed three times with modified
Eagle's medium, and binding was determined in modified Eagle's
medium containing 20 mM Hepes/0.1% bovine serum albumin con-
taining 125I-SM-C (5 ng/ml, 120 jCi/,gg). After a 2-hr incubation at
4VC, cells were washed three times in phosphate-buffered saline and
the cell-associated radioactivity was determined after solubilization
in 0.2M NaOH. Specific binding was determined as for Fig. 1. 0-0,
5% PPP. PDGF: 0-0, 4.8 Ag/ml; *-*-@, 3.4 Ag/ml; 0--*, 0.76
,Ag/ml.
(15% at 6 hr in modified Eagle's medium alone) by incubation
at 4VC. In addition, if the cultures were incubated for these
times in spent medium (medium that had been exposed to cells
for 3 days) rather than in PPP, the binding remained constant.
Therefore, simply changing the medium or handling the cul-
tures did not alter binding.
Sequential Exposure of Quiescent Cells to PDGF Followed
by Plasma Increases SM-C Binding. Transient exposure of
quiescent cells to PDGF allows initiation of DNA synthesis after
the cells are placed in medium supplemented with PPP. Be-
cause progression of competent cells to DNA synthesis requires
both SM-C and additional unidentified factors in PPP, we de-
termined if the sequential treatment of quiescent cells with
PDGF and then PPP could alter the 125I-SM-C binding ca-
pacity. Quiescent cells were incubated for 5 hr at 370C in me-
dium containing PDGF. This medium was removed, the cells
were washed and placed in medium containing 5% PPP or in
medium alone (control cultures), and 125I-SM-C binding was
determined after various times of incubation (Fig. 3).
There was a striking increase in binding during the first 3 hr
of incubation in only those cultures exposed to PDGF and then
to PPP. This was followed by a decrease in binding after 4-5
hr of continuous incubation in the PPP-supplemented medium
and a second increase at 6 hr. These increments in 125I-SM-C
binding were also temperature dependent; there was no in-
crease in SM-C binding when the plates were incubated under
identical conditions at 4°C. Quantitatively, maximal binding
was dependent on the concentration of platelet factor to which
quiescent cells were exposed and on the plasma concentration
used (optimal between 2.5% and 8% PPP). Several other vari-
ables may influence the magnitude of this increase. Previous
experiments have shown that the presence of native SM-C in
PPP would be expected to cause a decrease in SM-C binding
at this time (Fig. 1A). Because the maximal increase in binding
of 125I-SM-C ranged between 50% and 100% (interassay vari-
ance = 35%, mean of eight experiments) depending on the
sample of PPP used in the experiment, this variation could have
been affected by such variables as the amount of SM-C in PPP
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FIG 3. Effect of sequential addition of PDGF and then PPP
on 125I-SM-C binding. Confluent monolayers (312,000-350,000 cells
per dish) were washed three times with modified Eagle's medium and
fresh medium containing PDGF (5 ,ug/ml) was added. After a 5-hr
incubation, this medium was aspirated and fresh modified Eagle's
medium alone (O- -0) or containing 5% PPP (- 0) was added.
The cells were incubated for the times indicated; subsequently these
media were removed and 1251-SM-C binding was determined as for
Fig. 2. Each point represents the mean + SEM of eight experi-
ments.
different experiments. The transient exposure to PPP followed
by PDGF resulted in no change in SM-C binding.
SM-CDeficient Plasma. Because SM-C-deficient plasma
allows limited cell cycle progression to a point 6 hr prior to entry
into S phase, we determined if the factors contained in PPP that
stimulated increased 125I-SM-C binding were also present in
hypopituitary PPP. Cells exposed to PDGF and then to 5%
hypopituitary PPP showed a marked increase in 125I-SM-C
binding which exceeded that observed with normal PPP (Fig.
4). The time course of binding in hypopituitary PPP was similar
to that observed with normal PPP, but the loss of binding ob-
served between 3 and 5 hr with normal PPP was less pro-
nounced with SM-C-deficient PPP. Additionally, no second
peak of binding was observed when SM-C-deficient PPP was
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FIG. 4. Effect of sequential addition of PDGF and SM-C-defi-
cient PPP on 125I-SM-C binding. Quiescent cells (355,000 cells per
dish) were treated with PDGF (5.0 ,g/ml) as described for Fig. 3. This
medium was replaced with medium containing either PPP (o-*)
or SM-C-deficient PPP (O -- 0). After various times of incubation,
1251-SM-C binding was determined as for Fig. 2.
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Table 1. Effect of PDGF on DNA synthesis and
1265jSM-C binding
% increase in








significant decrease in binding capacity after 3 hr might be
attributed to the extremely low concentrations of SM-C in hy-
popituitary PPP because the addition of native SM-C to cultures
under these conditions has been demonstrated to result in ac-
celerated reduction in 125I-SM-C binding.
FGF Can Replace PDGF in Stimulation of SM-C Binding.
Because the preparation of PDGF used in these studies was not
homogeneous, FGF at a concentration of 50 ng/ml was added
to quiescent fibroblasts and incubated for 5 hr. This medium
then was removed and replaced with medium containing 5%
PPP. 125I-SM-C binding was determined at hourly intervals.
An increase of 125I-SM-C binding was observed that was similar
to that observed after cells were exposed to PDGF.
Potency of PDGF in Stimulating DNA Synthesis and
Binding. Increasing concentrations of PDGF were tested for
their capacity to stimulate both DNA synthesis and 125I-SM-C
binding after exposure to 5% PPP. With concentrations between
94 and 1250 ng/ml, PDGF induced an increasing fraction of
the cells to synthesize DNA (Table 1). Half-maximal stimulation
was apparent at 125 ng. When tested at the same concentration,
PDGF induced a 57% increase in 125I-SM-C binding at 250
ng/ml. The concentration of this partially purified material
used in the binding studies (0.5-5.0 ,g/ml) was capable of
stimulating greater than 95% of the nuclei to synthesize DNA
and stimulated a 71-102% increase in SM-C binding.
PDGF-Induced Increase in SM-C Binding Reflects an
Increase in Cell Receptor Number. Confluent quiescent
BALB/c 3T3 cells were exposed to PDGF and then transferred
to medium containing PPP as described for Fig. 4. At the time
of the addition of PPP-supplemented medium, and after 120
min, the cells were washed three times with phosphate-buffered
saline and 125I-SM-C binding was determined. Additional plates
processed in this manner received 125I-SM-C and increasing
concentrations of unlabeled SM-C (0.5-210 ng/ml). These ex-
periments, plotted by the method of Scatchard,f showed an
increase from 3.4 X 104 SM-C receptors per cell in quiescent
cells treated with PDGF alone to 6.2 X 104 receptors per cell
after an additional 2-hr incubation in 5% PPP (Fig. 5). The Kd
values were 6.71 X 10-10 and 6.78 X 1010, respectively.
DISCUSSION
These studies demonstrate that there are receptors for 125I-SM-C
in quiescent BALB/c 3T3 fibroblasts that bind this peptide at
concentrations of SM-C capable of permitting cell cycle pro-
gression. The binding reaction was time and temperature de-
pendent. The decrease in binding of 125I-SM-C observed after
t Use of the Scatchard plot of binding data in this study reflects the
prevailing use of this method of analysis in the study of hormone
binding to cells. This is the only analytical method available to
quantitatively measure the affinity of ligands and the number of
receptor sites per cell. For this reason, it continues to be used for this
purpose although its application to the analysis of cell receptor ligands
has not been rigorously justified thermodynamically.
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FIG. 5. Scatchard analysis of 125I-SM-C binding. Quiescent
monolayers (411,000 cells per dish) were treated with PDGF (5 ,ug/ml)
for 5 hr. Then the monolayers were washed with modified Eagle's
medium and divided into two groups. One group of monolayers was
exposed to 125J-SM-C (2.0 ng/ml) and increasing concentrations of
unlabeled SM-C (0.5-210 ng/ml) (lower curve). These plates were
incubated at 4°C for 2 hr, and cell-associated 1251-SM-C was deter-
mined as for Fig. 2. The second group received modified Eagle's me-
dium containing 5% SM-C-deficient PPP; the plates were incubated
for 2 hr at 37°C. This medium was removed and the cells were washed
twice. 125I-SM-C (2.0 ng/ml) plus increasing concentrations of unla-
beled SM-C were added and binding was determined as above (upper
curve). The results are plotted according to the method of Scatchard.
B/F, bound/free.
incubation for 90 min at 37°C (Fig. 1B) was not due to degra-
dation of SM-C and probably represents down-regulation of
SM-C receptors because cells so treated did not bind additional
125I-SM-C added at this time. This process has been described
for several labeled peptide growth factors (23, 24) and has been
attributed to the internalization of growth factor-receptor
complexes (25, 26).
Although the kinetics of the binding interaction between
several growth factors and their target cell receptor have been
characterized (27, 28), the control of the binding of a specific
growth factor by a second growth factor under physiologic
conditions has been subjected to limited investigation (29). In
previous studies, Fox et al. (18) have shown that PDGF can alter
the basal level of EGF binding in cultured cells; however, no
increase in EGF binding was reported. Our results extend these
observations by documenting the effect of PDGF on the
binding of SM-C to its receptor. PDGF was found to maintain
125I-SM-C binding, and this effect was concentration depen-
dent. Plasma was less effective than-PDGF in maintaining basal
receptor binding capacity and, when used individually, neither
brought about increased SM-C binding (Fig. 3). PDGF has been
postulated to alter EGF binding through direct interaction
between their respective receptors. Although our studies do not
directly address this question, they are consistent with this
hypothesis.
Because PDGF and plasma function synergistically to
stimulate DNA synthesis in quiescent cells and because SM-C
and other plasma factors are needed for progression, it was
reasonable to assume that PDGF plus these plasma components
might be required to induce a physiologic change in SM-C
binding. Sequential exposure of quiescent cells to PDGF and
then to plasma resulted in a doubling in binding capacity, which
occurred early in the cell cycle. This effect appeared to be
secondary to increased receptor number and not a change in
the affinity of the receptors for SM-C. This synergistic induction
was dependent on both PDGF and plasma concentration. These
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results support the hypothesis that PDGF and plasma factors
act in a sequential manner to stimulate cellular processes that
bring about DNA synthesis. PDGF exposure was required, al-
though its continued presence at the time of receptor induction
was not necessary. This finding implies that the biologic reaction
induced by PDGF exposure that led to receptor induction was
stable for at least 3 hr. The competent state induced by PDGF
has been shown to be stable for 13 hr (1).
Progression is a complex process which requires low molec-
ular weight nutrients, SM-C, and other unidentified factors
contained in SM-C-deficient PPP (4, 30, 31). The exact nature
of the factor(s) contained in hypopituitary PPP that facilitate
SM-C binding is unknown. However, it is not a low molecular
weight nutrient because PPP facilitate SM-C binding is un-
known. However, it is not a low molecular weight nutrient
because PPP from which these components have been removed
is active (unpublished results). Guinivan and Ladda (32) have
identified a substance released into the medium by transformed
rat kidney cells which enhances EGF binding. It is possible that
PDGF and hypopituitary PPP function synergistically to induce
the production of a similar substance by 3T3 cells.
PDGF in combination with SM-C-deficient plasma allows
limited progression of BALB/c 3T3 cells to a point 6 hr before
S phase, but SM-C is required for continued progression into
DNA synthesis. In the presence of either normal or hypopitu-
itary plasma, SM-C binding reaches a maximum at a time be-
fore SM-C is required for continued progression. Therefore,
PDGF and the factor(s) in SM-C-deficient plasma are exerting
their effects on SM-C binding at a time when they function
cooperatively to permit cell cycle progression. The occurrence
of a synergistic increase in SM-C receptor number well before
the 6-hr growth arrest point suggests that this increase might
be crucial for SM-C to stimulate progression.
Peptide growth factors interact with membranes prior to
exerting their effects in target cells. The capacity of one peptide
to modulate the receptor interaction of another has been ob-
served only recently (18). This may be a more widely applicable
mechanism whereby the response of normal cells to one growth
factor, which is required for division, is regulated by a second
growth factor. In addition, factors that have not been classically
defined as growth factors but that alter the normal response of
cells to growth factors might operate through this mechanism.
For example, tumor promoters such as phorbol ester or simian
virus 40 (33, 34) could enhance growth factor responsiveness
by altering growth factor-receptor interactions early in the cell
cycle.
Our results support the concept that multiple substances act
in concert to stimulate DNA synthesis and suggest at least one
mechanism by which multiple factors function synergistically
to. promote replication.
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